Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

@article{Hoff2004PhaseIT,
  title={Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer},
  author={Paulo Marcelo Gehm Hoff and Everardo Delforge Saad and Richard Pazdur and Robert A. Wolff and Yvonne Lassere and Karla R. Bogaard and James L Abbruzzese},
  journal={Investigational New Drugs},
  year={2004},
  volume={22},
  pages={307-313}
}
Background: Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined irinotecan and oxaliplatin given every three weeks… CONTINUE READING